Novel Therapies in the Treatment of Multiple Myeloma

Authors:
Jacob P. Laubach From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Jacob P. Laubach in
Current site
Google Scholar
PubMed Close
 MD, MPP
,
Constantine S. Mitsiades From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Constantine S. Mitsiades in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Anuj Mahindra From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Anuj Mahindra in
Current site
Google Scholar
PubMed Close
 MD
,
Robert L. Schlossman From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Robert L. Schlossman in
Current site
Google Scholar
PubMed Close
 MD
,
Teru Hideshima From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Teru Hideshima in
Current site
Google Scholar
PubMed Close
 MD, PhD
,
Dharminder Chauhan From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Dharminder Chauhan in
Current site
Google Scholar
PubMed Close
 PhD
,
Nicole A. Carreau From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Nicole A. Carreau in
Current site
Google Scholar
PubMed Close
 BS
,
Irene M. Ghobrial From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Irene M. Ghobrial in
Current site
Google Scholar
PubMed Close
 MD
,
Noopur Raje From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Noopur Raje in
Current site
Google Scholar
PubMed Close
 MD
,
Nikhil C. Munshi From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Nikhil C. Munshi in
Current site
Google Scholar
PubMed Close
 MD
,
Kenneth C. Anderson From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Kenneth C. Anderson in
Current site
Google Scholar
PubMed Close
 MD
, and
Paul G. Richardson From the Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medical Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

Search for other papers by Paul G. Richardson in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 7: Issue 9
Online Publication Date:
Oct 2009
DOI:
https://doi.org/10.6004/jnccn.2009.0062
Full access

Multiple myeloma (MM) is a clonal B-cell malignancy characterized by aberrant expansion of plasma cells within bone marrow and extramedullary sites. In 2009, 20,580 new cases of MM and 10,580 deaths from the disease occurred in the United States. Treatment traditionally consists of systemic chemotherapy, with adjunctive use of radiation or surgery in selected cases associated with extramedullary disease. The therapeutic landscape in MM has changed markedly in the past decade with the introduction of the novel immunomodulatory agents thalidomide and lenalidomide, and the first-in-class proteasome inhibitor bortezomib. Although MM remains an incurable malignancy, new approaches to therapy incorporating these agents have produced significantly higher response rates and improved intervals of both progression-free and overall survival in the context of randomized, controlled trials. In aggregate, the use of novel therapies in MM has been associated with substantial improvements in patient outcome.

Correspondence: Jacob P. Laubach, MD, Harvard Medical School and Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115. E-mail: jacobp_laubach@dfci.harvard.edu
  • Collapse
  • Expand
  • 1

    McKenna Rw, Kyle RA, Kuehl WM et al.. Plasma cell neoplasms. In: Swedlow SH, Campo E, Harris NL et al.., eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2008:200–213.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2

    Jemal A, Siegel R, Ward E et al.. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225–249.

  • 3

    Kumar SK, Rajkumar SV, Dispenzieri A et al.. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.

  • 4

    Anderson KC, Alsina M, Bensinger W et al.. NCCN clinical practice guidelines in oncology: multiple myeloma, version 2, 2010. Available at: http://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf. Accessed September 1, 2009.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5

    Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749–757.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6

    Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842–854.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7

    Greipp PR, San Miguel J, Durie BG et al.. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412–3420.

  • 8

    Stewart AK, Bergsagel PL, Greipp PR et al.. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007;21:529–534.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9

    Yeung J, Chang H. Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. J Clin Pathol 2008;61:832–836.

  • 10

    Gertz MA, Lacy MQ, Dispenzieri A et al.. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–2840.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11

    Chang H, Qi XY, Samiee S et al.. Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplant 2005;36:793–796.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12

    Avet-Loiseau H, Attal M, Moreau P et al.. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489–3495.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13

    Zhan F, Barlogie B, Arzoumanian V et al.. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007;109:1692–1700.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Shaughnessy JD Jr, Zhan F, Burington BE et al.. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–2284.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15

    Shaughnessy JD Jr, Haessler J, van Rhee F et al.. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol 2007;137:530–536.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Gertz MA, Lacy MQ, Dispenzieri A et al.. Impact of age and serum creatinine value on outcome after autologous blood stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2007;39:605–611.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17

    Oken MM, Harrington DP, Abramson N et al.. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997;79:1561–1567.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Anderson H, Scarffe JH, Ranson M et al.. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71:326–330.

  • 19

    Alexanian R, Barlogie B, Dixon D. High dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8–11.

  • 20

    Gertz MA, Garton JP, Greipp PR et al.. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995;9:2115–2118.

  • 21

    Gertz MA, Kalish LA, Kyle RA et al.. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995;18:475–480.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22

    Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71:25–30.

  • 23

    Phillips JK, Sherlaw-Johnson C, Pearce R et al.. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 1995;17:465–472.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Durie BGM, Dixon DO, Carter S et al.. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1986;4:1227–1237.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25

    Giles FJ, Wickham NR, Rapoport BL et al.. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000;63:125–130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26

    D’Amato RJ, Loughman MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082–4085.

  • 27

    Davies FE, Raje N, Hideshima T et al.. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210–216.

  • 28

    Geitz H, Handt S, Zwingengerger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996;32:213–221.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29

    Mitsiades N, Mitsiades CS, Poulaki V et al.. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525–4530.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30

    Singhal S, Mehta J, Desikan R et al.. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565–1571.

  • 31

    Barlogie B, Desikan R, Eddlemon P et al.. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492–494.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32

    van Rhee F, Dhodapkar M, Shaughnessy JD Jr et al.. First thalidomide clinical trial in multiple myeloma: a decade. Blood 2008;112:1035–1038.

  • 33

    Glasmacher A, Hahn C, Hoffmann F et al.. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132:584–593.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34

    Palumbo A, Bringhen S, Caravita T et al.. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825–831.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35

    Facon T, Mary JY, Hulin C et al.. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007;370:1209–1218.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36

    Rajkumar SV, Jacobus S, Callander N et al.. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2006;108:239a.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37

    Rajkumar SV, Rosinol L, Hussein M et al.. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008;26:2171–2177.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38

    Macro M, Divine M, Uzunhan Y et al.. Dexamethasone+thalidomide (dex/thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial [abstract]. Presented at the American Society of Hematology 48th Annual Meeting; December 9–12, 2006; Orlando, Florida. Abstract 800.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39

    Attal M, Harousseau JL, Leyvraz S et al.. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006;108:3289–3294.

  • 40

    Spencer A, Prince HM, Roberts AW et al.. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 2009;27:1788–1793.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41

    Barlogie B, Tricot G, Anaissie E et al.. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021–1030.

  • 42

    Barlogie B, Pineda-Roman M, van Rhee F et al.. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008;112:3115–3121.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43

    Morgan GJ, Jackson GH, Davies FE et al.. Maintenance thalidomide may improve progression free but not overall survival; results from the myeloma IX maintenance randomisation [abstract]. Presented at the American Society of Hematology 50th Annual Meeting; December 6–8, 2008; San Francisco, California. Abstract 656.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44

    Richardson P, Schlossman R, Jagannath S et al.. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004;79:875–882.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45

    Mileshkin L, Stark R, Day B,. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507–4514.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46

    Dimopoulos MA, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004;117:508–515.

  • 47

    Palumbo A, Facon T, Sonneveld P et al.. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008;111:3968–3977.

  • 48

    Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clin Proc 2005;80:1549–1551.

  • 49

    Kaur A, Yu SS, Lee AJ, Chiao TB. Thalidomide-induced sinus bradycardia. Ann Pharmacother 2003;37:1040–1043.

  • 50

    Badros AZ, Siegel E, Bodenner D et al.. Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002;112:412–413.

  • 51

    Trojan A, Chasse E, Gay B et al.. Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma. Ann Oncol 2003;14:501–502.

  • 52

    Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002;13:1636–1640.

  • 53

    Rajkumar SV, Gertz MA, Witzig TE. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma. N Engl J Med 2000;343:972–973.

  • 54

    Mitsiades N, Mitsiades CS, Poulaki V et al.. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4525–4530.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55

    Chang DH, Liu N, Klimek V et al.. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618–621.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56

    Dredge K, Horsfall R, Robinson SP et al.. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005;69:56–63.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57

    Breitkreutz I, Raab MS, Vallet S et al.. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008;22:1925–1932.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58

    Richardson PG, Schlossman RL, Weller E et al.. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063–3067.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59

    Richardson PG, Blood E, Mitsiades CS et al.. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458–3464.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60

    Weber DM, Chen C, Niesvizky R et al.. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133–2142.

  • 61

    Dimopoulos M, Spencer A, Attal M et al.. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123–2132.

  • 62

    Wang M, Dimopoulos MA, Chen C et al.. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112:4445–4451.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 63

    Knop S, Gerecke C, Liebisch P et al.. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113:4137–4143.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 64

    Morgan GJ, Schey SA, Wu P et al.. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137:268–269.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 65

    Lacy MQ, Gertz MA, Dispenzieri A et al.. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 2007;82:1179–1184.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 66

    Rajkumar S, Jacobus N, Callander R et al.. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: analysis of response, survival, and outcome [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 8504.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 67

    Castaneda CP, Zeldis JB, Freeman J et al.. RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf 2008;31:743–752.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 68

    Richardson P, Jagannath S, Schlossman R et al.. A multi-center, randomized, phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens when used alone or in combination with dexameyhasone (Dex) for the treatment of relapsed or refractory multiple myeloma (MM). Blood 2002;100:104a.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69

    Sviggum HP, Davis MD, Rajkumar SV, Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006;142:1298–1302.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70

    Hussain S, Browne R, Chen J, Parekh S. Lenalidomide-induced severe hepatotoxicity. Blood 2007;110:3814.

  • 71

    Thornburg A, Abonour R, Smith P et al.. Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide. Chest 2007;131:1572–1574.

  • 72

    Kumar S, Dispenzieri A, Lacy MQ et al.. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035–2042.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 73

    Mazumder A, Kaufman J, Niesvizky R et al.. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia 2008;22:1280–1281; author reply 1281–1282.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 74

    Hideshima T, Richardson P, Chauhan D et al.. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071–3076.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 75

    Hideshima T, Chauhan D, Richardson P et al.. NF-kB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639–16647.

  • 76

    Mitsiades N, Mitsiades CS, Richardson PG et al.. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377–2380.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 77

    Hideshima T, Mitsiades C, Akiyama M et al.. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530–1534.

  • 78

    Hideshima T, Chauhan D, Hayashi T et al.. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003;22:8386–8393.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 79

    von Metzler I, Krebbel H, Hecht M et al.. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21:2025–2034.

  • 80

    Mukherjee S, Raje N, Schoonmaker JA et al.. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118:491–504.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 81

    Orlowski RZ, Stinchcombe TE, Mitchell BS et al.. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420–4427.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 82

    Richardson PG, Barlogie B, Berenson J et al.. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.

  • 83

    Jagannath S, Barlogie B, Berenson J et al.. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165–172.

  • 84

    Richardson PG, Barlogie B, Berenson J et al.. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977–2981.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 85

    Richardson PG, Sonneveld P, Schuster MW et al.. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.

  • 86

    Richardson PG, Sonneveld P, Schuster M et al.. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557–3560.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 87

    Richardson PG, Barlogie B, Berenson J et al.. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316–1319.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 88

    Orlowski RZ, Nagler A, Sonneveld P et al.. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892–3901.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 89

    San Miguel JF, Schlag R, Khuageva NK et al.. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906–917.

  • 90

    Harousseau JL, Mathiot C, Attal M et al.. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM2005/01 trial [abstract]. J Clin Oncol 2008: 26(Suppl 1):Abstract 8505.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 91

    Sonneveld P, Van der Holt B, Schmidt-Wolf I et al.. First analysis of HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treartment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Presented at the American Society of Hematology 50th Annual Meeting; December 6–8, 2008; San Francisco, California. Abstract 653.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 92

    Richardson PG, Briemberg H, Jagannath S et al.. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113–3120.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 93

    Badros A, Goloubeva O, Dalal JS et al.. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110:1042–1049.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 94

    Richardson PG, Xie W, Mitsiades C et al.. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518–3525.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 95

    Lonial S, Waller EK, Richardson PG et al.. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777–3784.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 96

    Zappasodi P, Dore R, Castagnola C et al.. Rapid response to high-dose steroids of severe bortezomib-related pulmonary complication in multiple myeloma. J Clin Oncol 2007;25:3380–3381.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 97

    Duek A, Feldberg E, Haran M, Berrebi A. Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug. Am J Hematol 2007;82:502–503.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 98

    Miyakoshi S, Kami M, Yuji K et al.. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006;107:3492–3494.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 99

    Cavo M, Tacchetti P, Patriarca F et al.. Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide-dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma [abstract]. Presented at the American Society of Hematology 50th Annual Meeting; December 6–8, 2008; San Francisco, California. Abstract 158.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 100

    Mitsiades N, Mitsiades CS, Poulaki V et al.. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A 2002;99:14374–14379.

  • 101

    Richardson P, Jagannath S, Jakubowiak A et al.. Lenalidomide, bortezomib, and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (MM): encouraging response rates and tolerability with correlation of outcome and adverse cytogenetics in a phase II study [abstract]. Presented at the American Society of Hematology 50th Annual Meeting; December 6–8, 2008; San Francisco, California. Abstract 1742.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 102

    Richardson P, Lonial S, Jakubowiak A et al.. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a phase I/II study [abstract]. Presented at the American Society of Hematology 50th Annual Meeting; December 6–8, 2008; San Francisco, California. Abstract 92.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 103

    Richardson P, Lonial S, Jakubowiak A et al.. Lenalidomide, bortezomib, and dexamethasone has notable activity in high-risk first-line myeloma [abstract]. Presented at the 12th International Myeloma Workshop; Washington, DC; February 26–March 1, 2009. Abstract 224.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 104

    Kyle RA, Gertz MA, Witzig TE et al.. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21–33.

  • 105

    Roussou M, Kastritis E, Migkou M et al.. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008;49:890–895.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 106

    Chanan-Khan AA, Kaufman JL, Mehta J et al.. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604–2606.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 107

    Richardson PG, Mitsiades C, Schlossman R et al.. New drugs for myeloma. Oncologist 2007;12:664–689.

Copyright:
Copyright © 2009 by the National Comprehensive Cancer Network 2009
Page Numbers:
14
Article Category:
Research Article
Received:
05 Aug 2009
Accepted:
08 Sep 2009
Print Publication Date:
01 Oct 2009
Online Publication Date:
Oct 2009
Keywords:
Multiple myeloma; cytogenetics; chemotherapy; thalidomide; lenalidomide; bortezomib
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1471 96 38
PDF Downloads 381 47 6
EPUB Downloads 0 0 0